Living Well with Advanced Breast Cancer: Understanding Supportive Care Needs
Official title: Living Well With Advanced Breast Cancer
Run by Ohio State University Comprehensive Cancer Center · NCT07227038 · Data updated 2026-11-12
This project asks adults with advanced (stage IV) breast cancer and their caregivers about what supportive care has helped, what’s been hard, and what help they still need.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | Ohio State University Comprehensive Cancer Center Academic / other |
| Locations | 1 site (Columbus, Ohio) |
| Status | Recruiting |
| Started | January 13, 2026 |
| Main results expected | December 31, 2026 |
| Study ends | December 31, 2026 |
| Registry record updated | March 19, 2026 |
| Trial ID | NCT07227038 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (age 18+) with stage IV metastatic breast cancer diagnosed within the past five years who fit one of three LWABC-related cohorts (never referred, cancelled an appointment, or completed the program), as well as caregivers of ABC patients, are the intended participants.
✕Probably not a fit
People who cannot provide informed consent, those who do not meet the cohort definitions, or those unable to connect with the study site are unlikely to gain direct benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational project enrolls four cohorts—people with recent stage IV metastatic breast cancer who were never referred to, who cancelled, or who completed the Living Well With Advanced Breast Cancer (LWABC) program, and caregivers of ABC patients. Participants complete a survey and a semi-structured interview, and the team reviews medical history, treatment records, and demographic data. The study examines acceptability of the LWABC model and compares survivorship care engagement across cohorts. No experimental treatments are given; the study is non-interventional and focuses on patient experiences and care patterns.
Why it matters
Potential benefit: If successful, the findings could improve how supportive and survivorship services are offered to people living with metastatic breast cancer.
How similar studies have gone: Prior survivorship and supportive-care programs for metastatic breast cancer have generally shown positive but variable effects, so this work builds on existing approaches rather than introducing a wholly untested concept.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria:
* \* COHORT 1:
* Diagnosis of stage 4 metastatic breast cancer within the past 5 years
* Never been referred to the LWABC
* Adults age ≥ 18 years
* COHORT 2:
* Diagnosis of stage 4 metastatic breast cancer within the past 5 years
* Have cancelled an appointment with the LWABC
* Adults age ≥ 18 years
* COHORT 3:
* Been seen in the Medical Oncology Clinic at Stephanie Spielman Comprehensive Breast Center (SSCBC) within the past 5 years
* Completed an appointment with the LWABC
* Adults age ≥ 18 years
* COHORT 4:
* Caregivers for ABC patients
* Adults age ≥ 18 years
Exclusion Criteria:
* Patients who cannot provide own informed consent
Where it's running
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States Recruiting
Study contacts
- Principal investigator: Ashley P Davenport, MD — Ohio State University Comprehensive Cancer Center
- Study coordinator: The Ohio State University Comprehensive Cancer Center
- Email: OSUCCCClinicaltrials@osumc.edu
- Phone: 800-293-5066
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Combining Tumor Treating Fields with Cabozantinib or Pembrolizumab and Nab-Paclitaxel for Advanced Solid Tumors
This study is testing a new treatment that combines tumor treating fields with two different cancer drugs to see if it helps people with advanced solid tumors in the abdomen or chest.
-
Combining Olaparib with Cediranib or AZD6738 for Advanced Breast Cancer with BRCA Mutations
This study is testing if combining the drugs olaparib with either cediranib or AZD6738 can help women with advanced breast cancer that has BRCA mutations feel better after they’ve already tried other treatments.
-
Couples Coping Together Against Cancer: A Feasibility and Acceptability Look
This observational study tests whether a brokered program for patients with cancer and their partners is feasible and acceptable, and whether it may reduce distress over time.
-
Leuprolide versus goserelin to stop ovarian estrogen production in pre- or peri-menopausal women with breast cancer
This study tests whether two doses of leuprolide or goserelin better stops the ovaries from making estrogen in pre- or peri-menopausal women with breast cancer.
-
Safety of combining pidnarulex (CX-5461) with trastuzumab deruxtecan for HER2-positive, HER2-low/ultralow breast and other HER2-expressing solid tumors
This trial tests whether adding pidnarulex to trastuzumab deruxtecan is safe and finds the best dose for adults with HER2-positive, HER2-low/ultralow, or other HER2-expressing advanced or metastatic breast and solid tumors.
-
Photon VMAT craniospinal radiation for leptomeningeal disease from breast or non‑small cell lung cancer
This trial tests whether craniospinal irradiation delivered with photon VMAT can help adults whose breast cancer or non‑small cell lung cancer has spread to the meninges (leptomeningeal disease).
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.